AKTX net incomeQ3 2026-$4.84M
AKTX net income was -$4.84M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$6.40M a year earlier. For the full fiscal 2025 it was -$17.30M, compared with -$19.79M in fiscal 2024.
Akari Therapeutics plc (AKTX) financials
For the twelve months ended Sep 30, 2026, Akari Therapeutics plc reported -$29.40M of net income.
- Net income, TTM
- -$29.40M
- Cash
- $5.74M
- Market cap
- $15.8M
FY2016FY2025
FY2016FY2019
AKTX revenue and earnings growth
AKTX EPSQ3 2026$0.00
AKTX diluted EPS was $0.00 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was $0.00.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.81M | $6.98M | $5.45M | $9.56M | $9.13M | $8.82M | $8.74M | $11.80M | $23.29M | $17.31M |
| Selling, general and admin | $9.28M | $9.66M | $11.36M | $13.53M | $8.08M | $9.16M | $8.22M | $11.69M | $11.80M | $9.94M |
| Operating income | -$17.27M | -$21.64M | -$16.81M | -$23.09M | -$17.21M | -$17.98M | -$16.96M | -$20.79M | -$37.78M | -$27.25M |
| Interest expense | $100.0K | $244.0K | - | - | - | - | - | - | $0 | $0 |
| Pre-tax income | -$18.30M | -$19.79M | -$10.01M | -$17.7K | -$17.42M | -$17.08M | -$16.85M | -$20.50M | -$35.40M | -$18.14M |
| Income tax | -$1.00M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$17.30M | -$19.79M | -$10.01M | -$17.75M | -$17.42M | -$17.08M | -$16.85M | -$20.50M | -$35.40M | -$18.14M |
| EPS, basic | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.03 | -$0.02 |
| EPS, diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.01 | -$0.01 | -$0.03 | -$0.02 |
| Diluted shares | 67.33B | 23.89B | 9.79B | 6.24B | 4.29B | 3.16B | 1.83B | 1.54B | 1.25B | 1.18B |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.20M | $2.66M | $3.85M | $13.25M | $9.36M | $14.06M | $5.73M | $5.97M | $28.25M | $34.24M |
| Short-term investments | - | - | - | - | - | - | - | - | $0 | $10.02M |
| Current assets | $5.46M | $2.95M | $4.34M | $13.81M | $11.63M | $14.58M | $6.44M | $7.45M | $28.81M | $45.63M |
| Goodwill | $8.43M | $8.43M | - | - | - | - | - | - | - | - |
| Total assets | $47.89M | $50.56M | $4.36M | $13.83M | $11.65M | $14.60M | $6.48M | $8.03M | $29.05M | $45.87M |
| Current liabilities | $12.35M | $19.91M | $4.58M | - | - | - | - | $4.92M | $11.85M | $11.71M |
| Total liabilities | $19.56M | $28.33M | $4.58M | $12.04M | $6.09M | $5.22M | $6.47M | $4.92M | $11.90M | $11.77M |
| Shareholders' equity | $28.33M | $22.23M | -$229.0K | $1.79M | $5.55M | $9.38M | $7.6K | $4.37M | $22.24M | $34.10M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.57M | -$12.55M | -$16.43M | -$21.50M | -$18.85M | -$16.95M | -$12.92M | -$22.77M | -$31.60M | -$24.62M |
| Capital expenditures | - | - | - | - | - | - | $0 | $0 | $36.9K | $54.8K |
| Free cash flow | - | - | - | - | - | - | -$12.92M | -$22.77M | -$31.64M | -$24.68M |
| Investing cash flow | - | $382.0K | - | - | - | - | $0 | $0 | $9.99M | -$10.07M |
| Financing cash flow | $13.17M | $10.99M | $7.02M | $25.29M | $14.29M | $25.07M | $12.65M | $500.0K | $15.67M | $0 |
| Stock-based compensation | $2.89M | $2.25M | $1.15M | $735.0K | $314.6K | $325.5K | $1.05M | $1.65M | $2.73M | $3.93M |
| Depreciation and amortization | - | $14.0K | $4.0K | $4.0K | $4.1K | $8.9K | $19.2K | $35.8K | $42.4K | $39.9K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -61.1% | -89.0% | - | -991.0% | -313.7% | -182.0% | -221718.9% | -469.2% | -159.2% | -53.2% |
| Return on assets | -36.1% | -39.1% | -229.8% | -128.3% | -149.6% | -117.0% | -260.0% | -255.3% | -121.9% | -39.5% |
| Current ratio | 0.44 | 0.15 | 0.95 | - | - | - | - | 1.52 | 2.43 | 3.90 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.11M | $2.08M | $1.46M | $1.09M | $249.0K | $667.0K | $813.0K | $1.25M | $143.0K | $3.31M | $2.28M | $2.51M |
| Selling, general and admin | $2.57M | $2.52M | $2.17M | $2.14M | $1.98M | $2.45M | $2.71M | $3.05M | $1.71M | $2.24M | $3.71M | $2.58M |
| Operating income | -$4.68M | -$4.60M | -$15.76M | -$3.23M | -$7.40M | -$3.12M | -$3.52M | -$5.28M | -$2.93M | -$7.45M | -$5.99M | -$5.09M |
| Interest expense | $85.0K | $80.0K | $61.0K | -$126.0K | $121.0K | $50.0K | $55.0K | $124.0K | $69.0K | $51.0K | $0 | - |
| Pre-tax income | -$4.84M | -$4.81M | -$15.31M | -$5.21M | -$7.49M | -$1.90M | -$3.71M | -$3.77M | -$2.90M | - | - | - |
| Income tax | $0 | $0 | -$859.0K | $85.0K | -$1.09M | $0 | $0 | - | - | - | $0 | - |
| Net income | -$4.84M | -$4.81M | -$14.46M | -$5.30M | -$6.40M | -$1.90M | -$3.71M | -$3.77M | -$2.90M | -$7.56M | -$5.57M | -$4.14M |
| EPS, basic | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
| EPS, diluted | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 | - |
| Diluted shares | 265.89B | 143.32B | 118.76B | - | 65.33B | 62.94B | 54.59B | - | 24.39B | 18.84B | 13.45B | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.74M | $7.69M | $2.77M | $5.20M | $2.54M | $2.77M | $2.64M | $2.66M | $2.25M | $4.18M | $1.31M | $3.85M |
| Current assets | $6.28M | $8.32M | $3.59M | $5.46M | $2.95M | $3.30M | $3.35M | $2.95M | $2.73M | $5.08M | $2.77M | $4.34M |
| Goodwill | - | - | - | $8.43M | $8.43M | $8.43M | $8.43M | $8.43M | - | - | - | - |
| Total assets | $36.58M | $38.62M | $33.89M | $47.89M | $45.38M | $50.91M | $50.96M | $50.56M | $2.73M | $5.08M | $2.77M | $4.36M |
| Current liabilities | $12.98M | $13.94M | $13.41M | $12.35M | $15.57M | $17.14M | $20.91M | $19.91M | $9.43M | $8.78M | $6.33M | $4.58M |
| Short-term debt | - | - | - | - | - | - | - | - | $200.0K | $600.0K | $900.0K | - |
| Total liabilities | $19.08M | $20.03M | $19.51M | $19.56M | $22.69M | $25.31M | $29.21M | $28.33M | - | - | - | $4.58M |
| Shareholders' equity | $17.50M | $18.59M | $14.38M | $28.33M | $22.69M | $25.61M | $21.75M | $22.23M | -$6.69M | -$3.70M | -$3.55M | -$229.0K |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.22M | -$3.11M | -$2.49M | -$3.04M | -$2.12M | -$3.26M | -$2.15M | -$2.12M | -$1.49M | -$4.89M | -$4.04M | -$4.41M |
| Financing cash flow | $2.27M | $8.04M | $53.0K | $5.76M | $1.90M | $3.38M | $2.13M | $2.15M | -$443.0K | $7.76M | $1.51M | $3.52M |
| Stock-based compensation | $537.0K | $711.0K | $305.0K | $471.0K | $685.0K | $719.0K | $1.01M | $1.26M | $248.0K | $445.0K | $296.0K | $304.0K |
| Depreciation and amortization | - | - | - | - | - | - | - | $1.0K | $0 | $0 | $13.0K | $1.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.48 | 0.60 | 0.27 | 0.44 | 0.19 | 0.19 | 0.16 | 0.15 | 0.29 | 0.58 | 0.44 | 0.95 |
Source: XBRL data Akari Therapeutics plc files with the SEC, latest filing dated Nov 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
AKTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AKTX | - | - | -$29.40M | - | $15.8M |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $306.26B |
| ANNX | - | - | -$198.96M | - | $747.8M |
| OMER | - | - | $124.83M | - | $1.27B |
| KNSA | $945.96M | +58.2% | $109.57M | 11.6% | $7.57B |
AKTX FAQ
4 questionsIs AKTX profitable?
No. Akari Therapeutics plc reported a net loss of $29.40M for the twelve months ended Sep 30, 2026.How much cash and debt does AKTX have?
Akari Therapeutics plc reported $5.74M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did AKTX last report financial results?
The latest statements here come from Akari Therapeutics plc's 10-Q filed on Nov 12, 2026, covering the period ended Sep 30, 2026.Where does this AKTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Akari Therapeutics plc files with the SEC. It is provided for information only and is not investment advice.